A Phase 3 interventional study of Faricimab and Sham Procedure in Neovascular Age-related Macular Degeneration, sponsored by Hoffmann-La Roche. Completed at 251 sites in 27 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-10-24.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing faricimab in Macular Degeneration — 6 open to participants now, 7 under way, 2 of them phase 3. faricimab · Macular Degeneration.
Among the 14 studies testing faricimab in Macular Degeneration, this one has the largest enrollment, is the only one that started in 2021, is one of 3 in phase 3, and was the 3rd registered.
1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.
Browse Macular Degeneration studies →6 of the 14 studies testing faricimab in Macular Degeneration are open now, in 4 countries. Recruiting first, the newest first:
Junyeop Lee · Sites in Korea, Republic of
Ages 50+
Biobizkaia Health Research Institute · Sites in Spain
Ages 50+
Yeungnam University College of Medicine · Sites in Korea, Republic of
Ages 50+
Singapore National Eye Centre · Sites in Singapore
Ages 50+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 50+
By country, each count listing its studies:
faricimab: first FDA approval 2022 (VABYSMO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 4 · Phase 4 5
First in 2013; this study’s year is marked. 1 started in 2021.
This study's enrollment of 1,036 is above the median of 56 across 985 interventional studies indexed under Macular Degeneration.
Median enrollment 57 across the 14 interventional studies. Of the 6 that completed or were terminated, 3 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 14 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
32 studies in Macular Degeneration by Hoffmann-La Roche: 3 open now, 10 under way, 4 of them phase 3. Of 21 finished, 10 (48%) have results posted.
Among the 32 studies in Macular Degeneration by Hoffmann-La Roche, this one is the 3rd largest by enrollment of the 28 interventional ones that give a count, is one of 3 that started in 2021, is one of 14 in phase 3, and was the 21st registered.
Hoffmann-La Roche’s Macular Degeneration studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing faricimab in Macular Degeneration, from their registry updates:
Among Hoffmann-La Roche’s 32 in Macular Degeneration:
This tab as a report to print or save as PDF → With an account.
This main long-term extension study is designed to evaluate the long-term safety and tolerability of faricimab 6 milligrams (mg) administered by intravitreal injection at a personalized treatment interval (PTI) to participants with neovascular age-related macular degeneration (nAMD) who enrolled in and completed one of the Phase III studies: GR40306 (NCT03823287) or GR40844 (NCT03823300), also referred to as the parent studies. Eligible patients who consent to participate in this main study will be enrolled upon completion of the end-of-study visit in the parent study.
Additionally, there is a substudy that is being conducted. The aim of this substudy is to evaluate the impact of intravitreal faricimab on the health of the corneal endothelial cells in the study eyes of patients with nAMD to fulfill a U.S. Food and Drug Administration (FDA) post-marketing requirement. The fellow eyes of the same enrolled participants in the substudy will serve as the controls.
Inclusion Criteria for the Main Study:
Inclusion Criteria for the Substudy:
Exclusion Criteria for the Main Study:
Exclusion Criteria for the Substudy:
In addition to the exclusion criteria specified in the main Study GR42691, patients will be excluded from this substudy if they meet any of the following exclusion criteria:
Exclusion Criteria in Either Eye for the Substudy:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Faricimab · Other: Sham Procedure · Drug: Anti-VEGF Therapy
Drug: Faricimab · Drug: Anti-VEGF Therapy
Faricimab 6 mg will be administered by intravitreal (IVT) injection into the study eye according to the personalized treatment interval (PTI) dosing regimen for the duration of the study.
Also known as: RO6867461, RG7716
The sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. The sham procedure will be administered to participants as appropriate during the first 12 weeks of this study in order to maintain the masking of the initial faricimab PTI.
At the discretion of the principal investigator, participants were allowed to have their fellow (non-study) eye treated with the standard of care anti-VEGF therapy (if needed) according to region-specific anti-VEGF prescribing information for the recommended dose and frequency of treatment.
Incidence and Severity of Ocular Adverse Events in the Study Eye, With Severity Determined According to Adverse Event Severity Grading Scale
This is an analysis of participants with at least one ocular adverse event (AE) that occurred in the study eye. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of the seriousness, severity (e.g., mild, moderate, or severe intensity), and causality for each AE. AEs of special interest (AESI) included the following: Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, are associated with severe intraocular inflammation (IOI), or require surgical or medical intervention to prevent permanent loss of sight; suspected transmission of an infectious agent by the study drug; and, cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law.
Time frame: From the date of first administration of faricimab through 28 days after the end of study (up to 2 years)
Incidence of Ocular Adverse Events in the Fellow Eye
This is an analysis of participants with at least one ocular adverse event (AE) that occurred in the study eye. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of the seriousness, severity, and causality for each AE. AEs of special interest (AESI) included the following: Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, are associated with severe intraocular inflammation (IOI), or require surgical or medical intervention to prevent permanent loss of sight; suspected transmission of an infectious agent by the study drug; and, cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law.
Time frame: From the date of first administration of faricimab through 28 days after the end of study (up to 2 years)
Incidence and Severity of Non-Ocular Adverse Events, With Severity Determined According to Adverse Event Severity Grading Scale
This is an analysis of participants with at least one non-ocular (systemic) adverse event (AE). Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of the seriousness, severity (e.g., mild, moderate, or severe intensity), and causality for each AE. AEs of special interest (AESI) included the following: Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, are associated with severe intraocular inflammation (IOI), or require surgical or medical intervention to prevent permanent loss of sight; suspected transmission of an infectious agent by the study drug; and, cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law.
Time frame: From the date of first administration of faricimab through 28 days after the end of study (up to 2 years)
Substudy: Percent Change in Corneal Endothelial Cell Density From Baseline at 1 Year in the Study Eye as Compared With the Fellow Eye
Specular microscopy was performed for both eyes prior to application of any topical ophthalmic anesthetic, tonometry, or any other study treatment on the same day for the evaluation of corneal endothelial cell (CEC) density. The 1-year timepoint was defined as the earliest substudy visit closest to Week 52 occurring between Week 48 and Week 64. Data (from both study eye and fellow eye) collected after the fellow eye's use of prohibited therapies-such as faricimab, brolucizumab, bevacizumab, and Port Delivery System implantation-were excluded from the corneal endothelial cell analysis.
Time frame: Baseline and 1 year
Substudy: Percent Change in Corneal Endothelial Cell Density From Baseline at Week 24 in the Study Eye as Compared With the Fellow Eye
Specular microscopy was performed for both eyes prior to application of any topical ophthalmic anesthetic, tonometry, or any other study treatment on the same day for the evaluation of corneal endothelial cell (CEC) density. The Week 24 timepoint was defined as the earliest substudy visit closest to Week 24 occurring between Week 20 and Week 28. Data (from both study eye and fellow eye) collected after the fellow eye's use of prohibited therapies-such as faricimab, brolucizumab, bevacizumab, and Port Delivery System implantation-were excluded from the corneal endothelial cell analysis.
Time frame: Baseline and Week 24
A total of 1036 participants were enrolled in the main study, 7 of whom were excluded from analysis, resulting in a final analysis set of 1029 participants. A subgroup of 117 also participated concurrently in the substudy. Only 1 eye for each participant was assigned as the study eye in the prior parent studies, per the eligibility criteria, to receive study intervention; that study eye remained the same in this main study and substudy. The fellow (other) eye was not assigned to an intervention.
| Milestone | Main Study Cohort A: Faricimab PTI (Prior Faricimab) | Main Study Cohort B: Faricimab PTI (Prior Aflibercept) | Substudy: Faricimab PTI |
|---|---|---|---|
| Started | 524 | 505 | 0 |
| Safety-evaluable population | 520 | 505 | 0 |
| Completed | 453 | 415 | 0 |
| Not completed | 71 | 90 | 0 |
| Withdrew: Withdrawal by subject | 19 | 27 | 0 |
| Withdrew: Death | 13 | 27 | 0 |
| Withdrew: Subject missed the safety follow-up visit | 9 | 10 | 0 |
| Withdrew: Physician decision | 8 | 10 | 0 |
| Withdrew: Adverse event | 8 | 8 | 0 |
| Withdrew: Lost to follow-up | 9 | 4 | 0 |
| Withdrew: Reason not specified | 3 | 3 | 0 |
| Withdrew: Lack of efficacy | 1 | 1 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 |
| Milestone | Main Study Cohort A: Faricimab PTI (Prior Faricimab) | Main Study Cohort B: Faricimab PTI (Prior Aflibercept) | Substudy: Faricimab PTI |
|---|---|---|---|
| Started | 0 | 0 | 117 |
| Modified intent-to-treat and safety-evaluable population | 0 | 0 | 113 |
| Completed the year 1 substudy visit | 0 | 0 | 104 |
| Completed | 0 | 0 | 107 |
| Not completed | 0 | 0 | 10 |
| Withdrew: Withdrawal by subject | 0 | 0 | 4 |
| Withdrew: Prohibited medication | 0 | 0 | 2 |
| Withdrew: Adverse event | 0 | 0 | 1 |
| Withdrew: Cataract surgery | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 |
| Withdrew: Physician decision | 0 | 0 | 1 |
This is an analysis of participants with at least one ocular adverse event (AE) that occurred in the study eye. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of the seriousness, severity (e.g., mild, moderate, or severe intensity), and causality for each AE. AEs of special interest (AESI) included the following: Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, are associated with severe intraocular inflammation (IOI), or require surgical or medical intervention to prevent permanent loss of sight; suspected transmission of an infectious agent by the study drug; and, cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law.
| Participants | Main Study Cohort A: Faricimab PTI (Prior Faricimab) | Main Study Cohort B: Faricimab PTI (Prior Aflibercept) | Substudy: Faricimab PTI |
|---|---|---|---|
| Any Adverse Event (AE), Any Severity | 188 | 207 | 16 |
| AEs by Severity: Mild | 114 | 106 | 11 |
| AEs by Severity: Moderate | 58 | 75 | 4 |
| AEs by Severity: Severe | 13 | 23 | 1 |
| AEs by Severity: Missing | 3 | 3 | 0 |
| Serious Adverse Event (SAE) | 18 | 27 | 1 |
| AE Leading to Withdrawal from Study Treatment | 4 | 5 | 0 |
| Treatment-related AE | 8 | 12 | 2 |
| Treatment-related SAE | 1 | 3 | 1 |
| Any AE of Special Interest (AESI) | 15 | 21 | 1 |
| AESI: Drop in Visual Acuity Score ≥30 Letters | 11 | 16 | 1 |
| AESI: Associated with Severe IOI | 1 | 2 | 0 |
| AESI: Intervention Required to Prevent Permanent Vision Loss | 3 | 3 | 0 |
| AESI: Suspected Transmission of Infectious Agent by Study Drug | 0 | 0 | 0 |
This is an analysis of participants with at least one ocular adverse event (AE) that occurred in the study eye. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of the seriousness, severity, and causality for each AE. AEs of special interest (AESI) included the following: Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, are associated with severe intraocular inflammation (IOI), or require surgical or medical intervention to prevent permanent loss of sight; suspected transmission of an infectious agent by the study drug; and, cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law.
| Participants | Main Study Cohort A: Faricimab PTI (Prior Faricimab) | Main Study Cohort B: Faricimab PTI (Prior Aflibercept) | Substudy: Faricimab PTI |
|---|---|---|---|
| Any Adverse Event (AE), Any Severity | 157 | 149 | 17 |
| Serious Adverse Event (SAE) | 4 | 11 | 1 |
| Any AE of Special Interest (AESI) | 3 | 11 | 1 |
| AESI: Drop in Visual Acuity Score ≥30 Letters | 3 | 8 | 0 |
| AESI: Associated with Severe IOI | 0 | 0 | 0 |
| AESI: Intervention Required to Prevent Permanent Vision Loss | 0 | 3 | 1 |
| AESI: Suspected Transmission of Infectious Agent by Study Drug | 0 | 0 | 0 |
This is an analysis of participants with at least one non-ocular (systemic) adverse event (AE). Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of the seriousness, severity (e.g., mild, moderate, or severe intensity), and causality for each AE. AEs of special interest (AESI) included the following: Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, are associated with severe intraocular inflammation (IOI), or require surgical or medical intervention to prevent permanent loss of sight; suspected transmission of an infectious agent by the study drug; and, cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law.
| Participants | Main Study Cohort A: Faricimab PTI (Prior Faricimab) | Main Study Cohort B: Faricimab PTI (Prior Aflibercept) | Substudy: Faricimab PTI |
|---|---|---|---|
| Any Adverse Event (AE), Any Severity | 343 | 337 | 41 |
| AE by Severity: Mild | 122 | 120 | 15 |
| AE by Severity: Moderate | 138 | 124 | 17 |
| AE by Severity: Severe | 83 | 93 | 9 |
| Serious Adverse Event (SAE) | 110 | 127 | 13 |
| AE Leading to Withdrawal from Study Treatment | 3 | 9 | 0 |
| Any AE of Special Interest (AESI) | 0 | 0 | 0 |
| AESI: Elevated ALT or AST with Either Elevated Bilirubin or Clinical Jaundice | 0 | 0 | 0 |
Specular microscopy was performed for both eyes prior to application of any topical ophthalmic anesthetic, tonometry, or any other study treatment on the same day for the evaluation of corneal endothelial cell (CEC) density. The 1-year timepoint was defined as the earliest substudy visit closest to Week 52 occurring between Week 48 and Week 64. Data (from both study eye and fellow eye) collected after the fellow eye's use of prohibited therapies-such as faricimab, brolucizumab, bevacizumab, and Port Delivery System implantation-were excluded from the corneal endothelial cell analysis.
| Percent change in cell density | Substudy: Faricimab PTI in the Study Eye | Substudy: Fellow Eye |
|---|---|---|
| Substudy: Percent Change in Corneal Endothelial Cell Density From Baseline at 1 Year in the Study Eye as Compared With the Fellow Eye | -0.51 (-1.68 to 0.65) | -0.71 (-1.53 to 0.10) |
Specular microscopy was performed for both eyes prior to application of any topical ophthalmic anesthetic, tonometry, or any other study treatment on the same day for the evaluation of corneal endothelial cell (CEC) density. The Week 24 timepoint was defined as the earliest substudy visit closest to Week 24 occurring between Week 20 and Week 28. Data (from both study eye and fellow eye) collected after the fellow eye's use of prohibited therapies-such as faricimab, brolucizumab, bevacizumab, and Port Delivery System implantation-were excluded from the corneal endothelial cell analysis.
| Percent change in cell density | Substudy: Faricimab PTI in the Study Eye | Substudy: Fellow Eye |
|---|---|---|
| Substudy: Percent Change in Corneal Endothelial Cell Density From Baseline at Week 24 in the Study Eye as Compared With the Fellow Eye | -0.02 (-0.86 to 0.81) | -0.29 (-0.92 to 0.33) |
Collected over From the date of first administration of faricimab through 28 days after the end of study (up to 2 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Main Study Cohort A: Faricimab PTI (Prior Faricimab) | 13/520 (2.5%) | 125/520 (24%) | 158/520 (30.4%) |
| Main Study Cohort B: Faricimab PTI (Prior Aflibercept) | 27/505 (5.3%) | 156/505 (30.9%) | 169/505 (33.5%) |
| Substudy: Faricimab PTI | 1/113 (0.9%) | 14/113 (12.4%) | 9/113 (8%) |
| Event | Main Study Cohort A: Faricimab PTI (Prior Faricimab) | Main Study Cohort B: Faricimab PTI (Prior Aflibercept) | Substudy: Faricimab PTI |
|---|---|---|---|
| Neovascular age-related macular degenerationEye disorders | 4/520 | 14/505 | 0/113 |
| PneumoniaInfections and infestations | 6/520 | 9/505 | 0/113 |
| COVID-19Infections and infestations | 8/520 | 5/505 | 0/113 |
| Cardiac failure congestiveCardiac disorders | 6/520 | 7/505 | 1/113 |
| CataractEye disorders | 5/520 | 7/505 | 0/113 |
| FallInjury, poisoning and procedural complications | 4/520 | 7/505 | 1/113 |
| Myocardial infarctionCardiac disorders | 2/520 | 6/505 | 0/113 |
| Atrial fibrillationCardiac disorders | 3/520 | 5/505 | 1/113 |
| Cerebrovascular accidentNervous system disorders | 5/520 | 5/505 | 1/113 |
| AnaemiaBlood and lymphatic system disorders | 0/520 | 1/505 | 1/113 |
| Event | Main Study Cohort A: Faricimab PTI (Prior Faricimab) | Main Study Cohort B: Faricimab PTI (Prior Aflibercept) | Substudy: Faricimab PTI |
|---|---|---|---|
| CataractEye disorders | 56/520 | 63/505 | 2/113 |
| COVID-19Infections and infestations | 61/520 | 48/505 | 5/113 |
| Neovascular age-related macular degenerationEye disorders | 60/520 | 55/505 | 2/113 |
| Posterior capsule opacificationEye disorders | 14/520 | 26/505 | 1/113 |
The number enrolled in the GR42691 main study and overall was 1036 participants, 7 of whom were excluded from analysis as an outcome of the GCP non-compliance audit finding at one site. Therefore, 1029 participants in total were included for analysis of the main study. The GR42691 substudy enrolled a subgroup of 117 participants from the main study; 113 of those participants received at least one injection of faricimab in the study eye during the substudy and were included for analysis.
| Age, Continuous(Years) | Main Study Cohort A: Faricimab PTI (Prior Faricimab) | Main Study Cohort B: Faricimab PTI (Prior Aflibercept) | Substudy: Faricimab PTI | Total |
|---|---|---|---|---|
| Main Study | 76.4 ± 8.2 | 77.7 ± 8.8 | — | 77.0 ± 8.5 |
| Substudy | — | — | 75.6 ± 8.1 | 75.6 ± 8.1 |
| Sex: Female, Male(Participants) | Main Study Cohort A: Faricimab PTI (Prior Faricimab) | Main Study Cohort B: Faricimab PTI (Prior Aflibercept) | Substudy: Faricimab PTI | Total |
|---|---|---|---|---|
| Main Study — Female | 308 | 291 | 0 | 599 |
| Main Study — Male | 216 | 214 | 0 | 430 |
| Substudy — Female | 0 | 0 | 61 | 61 |
| Substudy — Male | 0 | 0 | 52 | 52 |
| Ethnicity (NIH/OMB)(Participants) | Main Study Cohort A: Faricimab PTI (Prior Faricimab) | Main Study Cohort B: Faricimab PTI (Prior Aflibercept) | Substudy: Faricimab PTI | Total |
|---|---|---|---|---|
| Main Study — Hispanic or Latino | 50 | 53 | 0 | 103 |
| Main Study — Not Hispanic or Latino | 463 | 445 | 0 | 908 |
| Main Study — Unknown or Not Reported | 11 | 7 | 0 | 18 |
| Substudy — Hispanic or Latino | 0 | 0 | 23 | 23 |
| Substudy — Not Hispanic or Latino | 0 | 0 | 90 | 90 |
| Substudy — Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Main Study Cohort A: Faricimab PTI (Prior Faricimab) | Main Study Cohort B: Faricimab PTI (Prior Aflibercept) | Substudy: Faricimab PTI | Total |
|---|---|---|---|---|
| Main Study — American Indian or Alaska Native | 2 | 2 | 0 | 4 |
| Main Study — Asian | 76 | 83 | 0 | 159 |
| Main Study — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Main Study — Black or African American | 1 | 5 | 0 | 6 |
| Main Study — White | 433 | 402 | 0 | 835 |
| Main Study — More than one race | 0 | 1 | 0 | 1 |
| Main Study — Unknown or Not Reported | 12 | 12 | 0 | 24 |
| Substudy — American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Substudy — Asian | 0 | 0 | 0 | 0 |
| Substudy — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Substudy — Black or African American | 0 | 0 | 1 | 1 |
| Substudy — White | 0 | 0 | 112 | 112 |
| Substudy — More than one race | 0 | 0 | 0 | 0 |
| Substudy — Unknown or Not Reported | 0 | 0 | 0 | 0 |
Showing the first 100 of 251 sites across 27 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Ran from Apr 2021 to primary completion in Sep 2024, 40 months.
Results were first posted in Oct 2025, 1 year 1 month after primary completion.
Of 77 industry-sponsored phase 3 interventional studies under Macular Degeneration, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 40 months is above that.
Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 20 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Faricimab